Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD5335 |
| Synonyms | |
| Therapy Description |
AZD5335 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) linked to a topoisomerase 1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (8_Supplement): LB025). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD5335 | AZD 5335|AZD-5335 | FOLR1-targeted Therapy 24 | AZD5335 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) linked to a topoisomerase 1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (8_Supplement): LB025). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07218809 | Phase III | Topotecan Paclitaxel Pegylated liposomal doxorubicin Mirvetuximab Soravtansine AZD5335 | AZD5335 vs. Mirvetuximab Soravtansine in FRa-high and AZD5335 vs. Chemotherapy in FRa-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) | Recruiting | USA | SWE | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 5 |
| NCT05797168 | Phase Ib/II | AZD5335 + Saruparib AZD5335 | Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA) | Recruiting | USA | TUR | ISR | GBR | ESP | DEU | CAN | AUS | 4 |
CKB BOOST